25.20
-1.68%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Tong Ren Tang Co
Its shares trade on Shanghai under the ticker 600085.SS. It has been listed since 25 June 1997. In the fiscal year to 31 December 2025, it reported revenue of CN¥17.26bn and net income of CN¥1.19bn. At that date it held total assets of CN¥30.62bn and shareholders' equity of CN¥13.66bn.
Beijing Tong Ren Tang Co., Ltd. engages in the research, production, sale, and distribution of Chinese medicines. The company is headquartered in Beijing, Beijing. The Company’s main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and donkey-hide gelatin series. The firm distributes its products under the brand of Tongrentang. The firm is also involved in the operation of Tongrentang drug stores. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jun 1997
- Employees
- 18,065
- Website
- gf.tongrentang.com ↗
Leadership
Pay as last reported
- Mr. Shubing DiChairman of the Board, since 2019CN¥1.2m
- Ms. Kaiting WenChief Accounting Officer, Director, since 2020CN¥1.0m
- Mr. Zhiqiang TangGeneral CounselCN¥759,200
- Ms. Zhaohua ZhangGeneral Manager, Director, since 2019CN¥1.9m
- Ms. Li FengDeputy General Manager, Secretary of the BoardCN¥994,300
- Mr. Lingyun DongDeputy General Manager
- Mr. Tian WangDeputy General ManagerCN¥988,500
- Mr. Chunyou ZhangExecutive Deputy General ManagerCN¥1.1m
- Ms. Dongmei HuangDirector
- Mr. Kai SunDirector
- Ms. Chunrui WangDirector
- Mr. Li YangDirector, since 2021CN¥993,400
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 76
- Social
- 62
- Governance
- 45
- Direct emissions (scope 1)
- 34,974.17 t
- Energy emissions (scope 2)
- 77,586.56 t
- Women in the workforce
- 67.92%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beijing Tong Ren Tang employs 18,065 full-time employees for pharmaceutical production.
- Tongrentang brand distributes liuwei dihuang series in domestic and overseas markets.
- Tongren dahuoluo series is a key product for the company's pharmaceutical business.
Weaknesses
- Beijing Tong Ren Tang has no overseas manufacturing facilities for its products.
- The company relies solely on domestic market sales for its pharmaceutical revenue.
- Tongren niuhuang qingxin series faces limited international market penetration.
Opportunities
- Expanding the angong niuhuang series into new international markets.
- Increasing donkey-hide gelatin series sales in the Asian market.
- Growing the Tongrentang drug store network in China.
Threats
- Competition from domestic pharmaceutical companies in China.
- Regulatory changes affecting Chinese medicine exports.
- Economic downturns impacting consumer spending on health products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.